The VAD-DCEP sequence is an effective pre-transplant therapy in untreated multiple myeloma

Haematologica

Volumn 89, Issue 9, 2004, Pages 1124-1127

  Corso, Alessandro ^a   Barbarano, Luciana ^b   Zappasodi, Patrizia ^b   Cairoli, Roberto ^b   Alessandrino, Emilio Paolo ^b   Mangiacavalli, Silvia ^b   Ferrari, Daris ^b   Fava, Sergio ^b   Fiumanò, Mario ^b   Frigerio, Guido ^b   Isa, Luciano ^b   Luraschi, Annalisa ^b   Klersy, Catherine ^b   De Paoli, Alberto ^b   Vergani, Claudio ^b   Banfi, Luciano ^b   Perego, Daniele ^b   Ucci, Gianni ^b   Pinotti, Graziella ^b   Savarè, Maria ^b   Uziel, Lilj ^b   Vismara, Alessandro ^b   Morra, Enrica ^b   Lazzarino, Mario ^b   more..

^a FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^b NONE

Author keywords

CD34+ cells; DCEP; HDCTX; High dose therapy; Mobilization

Indexed keywords

CD34 ANTIGEN; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; VINCRISTINE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL PROTOCOL; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HOSPITALIZATION; HUMAN; HUMAN CELL; INFECTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEUTROPENIA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PULSATILE DRUG RELEASE; STEM CELL MOBILIZATION; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; COHORT STUDIES; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HEMATOPOIETIC STEM CELL MOBILIZATION; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; NEOADJUVANT THERAPY; NEUTROPENIA; THROMBOCYTOPENIA; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINCRISTINE;

EID: 4644363139     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet JG, Rossi JF, et al. A prospective randomised trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996;335:91-7.
2. Cunningham D, Paz-Ares L, Milan S, Powles R, Nicolson H, Hickish T, et al. High dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994;12:759-63.
3. Tricot G, Jagannath S, Vesole DH, Bracy D, Desikan KR, Siegel D, et al. Hematopoietic stem cell transplants for multiple myeloma. Leuk Lymphoma 1996;55:25-36.
4. Vesole DH, Tricot G, Jagannath S, Desikan KR, Siegel D, Bracy D, et al. Autotransplants in multiple myeloma: what have we learned? Blood 1996;88:838-47.
5. Desikan KR, Barlogie B, Jagannath S, Vesole DH, Siegel D, Fassas A, et al. Comparable engraftment kinetics following peripheral-blood stem-cell infusion mobilized with granulocyte colony-stimulating factor with or without cyclophosphamide in multiple myeloma. J Clin Oncol 1998;16:1547-53
6. Martinez E, Sureda A, De Dalmases C, Sanchez JA, Amill B, Togués D, et al. Mobilisation of peripheral blood progenitor cells by cyclophosphamide and rhGM-CSF in multiple myeloma. Bone Marrow Transplant 1996;18:1-7.
7. 2) and granulocyte colony-stimulating factor in patients with multiple myeloma. Bone Marrow Transplant 1996;17:691-7.
8. Demirer T, Buckner CD, Gooley T, Appelbaum FR, Rowley S, Chauncey T, et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1996;17:937-41.
9. Alegre A, Diaz-Mediavilla J, San Miguel J, Martinez R, Garcia Lorana J, Sureda A, et al. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish registry. Spanish Registry for Transplant in multiple myeloma and PETHEMA. Bone Marrow Transplant 1998;21:133-40.
10. Lazzarino M, Corso A, Barbarano L, Alessandrino EP, Cairoli R, Pinotti G, et al. DCEP (dexamethasone, cyclophosphamide, etoposide and cis-platin) is an effective regimen for peripheral blood stem cell collection in multiple myeloma. Bone Marrow Transplant 2001;28:835-9.
11. Corso A, Arcaini L, Caberlon S, Zappasodi P, Mangiacavalli S, Lorenzi A, et al. A combination of dexamethasone, cyclophosphamide, etoposide and cisplatin is less toxic and more effective than high-dose cyclophosphamide for peripheral stem cell mobilisation in multiple myeloma. Haematologica 2002;87:1041-5.
12. Desikan KR, Munshi N, Zangari M, Badros A, Anaissie E, Tricot G, et al. DCEP consolidation chemotherapy after two cycles of melphalan based high-dose therapy. High incidence of CR and superior outcome in comparison with matched historical controls. Blood 1999; 94 Suppl 1: a1411 [abstract].
13. Desikan KR, Munshi NC, Jagannath S, Siegel D, Bracy D, Tricot G, et al. Dexamethasone, cyclophosphamide, etoposide and cis-platinum (DCEP), an effective regimen for relapse after high-dose chemotherapy and autologous transplantation. Blood 1996;88 Suppl 1:a2331 [abstract].
14. Barlogie B. High-dose therapy and innovative approaches to treatment of multiple myeloma. Semin Hematol 1996; 38 Suppl 2:21-7.
15. Bjorkstrand B, Goldstone AH, Ljungman P, Brandt L, Brunet S, Carlson K, et al. Prognostic factors in autologous stem cell transplantation for multiple myeloma: an EBMT Registry Study. European Group for Bone Marrow Transplantation. Leuk Lymphoma 1994;15:265-72.
16. Lenhoff S, Hjorth M, Holmberg E, Turesson I, Westin J, Nielsen JL, et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood 2000;95:7-11.
17. Catley L, Anderson k. Strategies to improve the outcome of stem cell transplantation in multiple myeloma. Hematol J 2004;5:9-23.
18. Barlogie B, Jagannath S, Vesole D, Nauckes B, Cheson B, Mattox S, et al. Superiority of tandem autologous transplantation over standard therapy for previously untreated multiple myeloma. Blood 1997; 89:789-93.
19. Nadal E, Ginè E, Bladè J, Esteve J, Rosinol L, Fernàndez-Avilés, et al. High-dose therapy/autologous stem cell transplantation in patients with chemosensitive multiple myeloma: predictors of complete remission. Bone Marrow Transplant 2004;33:61-4.
20. Cook G, Marinaki P, Farrel E, Pearson C, Alcorn MJ, Sharp RA, et al. Peripheral blood progenitor cell mobilisation in patients with multiple myeloma following oral idarubicin and dexamethasone (Z-Dex) induction therapy. Leukemia 1997;11 Suppl 5:35-40.
21. Fermand JP, Levy Y, Gerota J, Benbunan M, Cosset JM, Castaigne S, et al. Treatment of multiple myeloma by high dose chemotherapy and total body irradiation followed by blood stem cells autologous graft. Blood 1989;73:20-3.
22. Barlogie B, Jagannath S, Desikan KR, Mattox S, Vesole D, Siegel D, et al. Total therapy with tandem transplants for newly diagnosed multiple myeloma. Blood 1999;93:55-65.
23. Dimopoulos M, Weber D, Kantarjian H, Delasalle KB, Alexanian R. HypeCVAD for VAD-resistant multiple myeloma. Am J Hematol 1996;52:77-81.